Fig. 3

Effects of specific inhibitors on CYP-mediated STS (10 µM) metabolism in HLMs. The concentration of CHL was 5 µM, while that for the other specific inhibitors was 1 µM. Each data point represents the mean ± SD of triple determinations (n = 3). In the presence of KET (1 µM), the MCR of STS decreased to 27.28 % of the control value, while the other inhibitors had no significant inhibitory effects on the metabolism of STS. FUR furafylline, specific inhibitor of CYP1A2; TRA trans-2-phenylcyclopropylamine, specific inhibitor of CYP2A6; SUL sulfaphenazole, specific inhibitor of CYP2C9; QUI quinidine, specific inhibitor of CYP2D6; CHL: chlormethiazole, specific inhibitor of CYP2E1; TICticlopidine, specific inhibitor of CYP2C19; KET ketoconazole, specific inhibitor of CYP3A4